TGen Team Hopes $2M Study Will Help Lay Path for Liquid Biopsy Monitoring in Metastatic Melanoma

NEW YORK (GenomeWeb) – Led by a team from the Translational Genomics Research Institute, researchers are pushing forward to test whether circulating DNA mutations might be a better way to monitor the disease progress and drug responses of metastatic melanoma patients than current imaging tools.

Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Be the first to comment

Leave a Reply

Your email address will not be published.